BR112022010278A2 - Terapia combinada que envolve compostos macrocíclicos de diarila - Google Patents
Terapia combinada que envolve compostos macrocíclicos de diarilaInfo
- Publication number
- BR112022010278A2 BR112022010278A2 BR112022010278A BR112022010278A BR112022010278A2 BR 112022010278 A2 BR112022010278 A2 BR 112022010278A2 BR 112022010278 A BR112022010278 A BR 112022010278A BR 112022010278 A BR112022010278 A BR 112022010278A BR 112022010278 A2 BR112022010278 A2 BR 112022010278A2
- Authority
- BR
- Brazil
- Prior art keywords
- diaril
- macrocyclic
- compounds
- combined therapy
- therapy involving
- Prior art date
Links
- 238000002648 combination therapy Methods 0.000 title abstract 2
- 150000001875 compounds Chemical class 0.000 title abstract 2
- 229940124785 KRAS inhibitor Drugs 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- -1 diaryl macrocycle Chemical class 0.000 abstract 1
- 229940125399 kras g12c inhibitor Drugs 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962941026P | 2019-11-27 | 2019-11-27 | |
| US202062981822P | 2020-02-26 | 2020-02-26 | |
| US202063005681P | 2020-04-06 | 2020-04-06 | |
| PCT/US2020/062390 WO2021108682A1 (en) | 2019-11-27 | 2020-11-25 | Combination therapy involving diaryl macrocyclic compounds |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112022010278A2 true BR112022010278A2 (pt) | 2022-10-04 |
Family
ID=76129920
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112022010278A BR112022010278A2 (pt) | 2019-11-27 | 2020-11-25 | Terapia combinada que envolve compostos macrocíclicos de diarila |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US11654145B2 (https=) |
| EP (1) | EP4065125A4 (https=) |
| JP (1) | JP7670711B2 (https=) |
| KR (1) | KR20220133866A (https=) |
| CN (1) | CN114901286B (https=) |
| AU (1) | AU2020391222A1 (https=) |
| BR (1) | BR112022010278A2 (https=) |
| CA (1) | CA3162632A1 (https=) |
| IL (1) | IL293206A (https=) |
| MX (1) | MX2022006500A (https=) |
| TW (1) | TW202133855A (https=) |
| WO (1) | WO2021108682A1 (https=) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2021154929A1 (en) * | 2020-01-31 | 2021-08-05 | Verastem, Inc. | Combination therapy for treating abnormal cell growth |
| US20220323446A1 (en) * | 2021-03-17 | 2022-10-13 | Amgen Inc. | Sotorasib dosing regimen |
| US11873296B2 (en) | 2022-06-07 | 2024-01-16 | Verastem, Inc. | Solid forms of a dual RAF/MEK inhibitor |
| WO2025148858A1 (zh) * | 2024-01-08 | 2025-07-17 | 应世生物科技(南京)有限公司 | FAK抑制剂和Pan-RAS抑制剂 |
| WO2025157162A1 (zh) * | 2024-01-22 | 2025-07-31 | 应世生物科技(南京)有限公司 | Fak抑制剂与kras g12c抑制剂的联用 |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2010319322A1 (en) * | 2009-11-13 | 2012-05-31 | Infinity Pharmaceuticals, Inc. | Compositions, kits, and methods for identification, assessment, prevention, and therapy of cancer |
| ES2933350T3 (es) * | 2014-01-24 | 2023-02-06 | Turning Point Therapeutics Inc | Macrociclos de diarilo como moduladores de proteína quinasas |
| JO3556B1 (ar) * | 2014-09-18 | 2020-07-05 | Araxes Pharma Llc | علاجات مدمجة لمعالجة السرطان |
| AU2016287568B2 (en) * | 2015-07-02 | 2020-08-20 | Turning Point Therapeutics, Inc. | Chiral diaryl macrocycles as modulators of protein kinases |
| RU2765181C2 (ru) * | 2015-07-06 | 2022-01-26 | Тёрнинг Поинт Терапьютикс, Инк. | Полиморфная форма диарильного макроцикла |
| EP3368039A1 (en) * | 2015-10-26 | 2018-09-05 | The Regents of The University of Colorado, A Body Corporate | Point mutations in trk inhibitor-resistant cancer and methods relating to the same |
| TWI808958B (zh) * | 2017-01-25 | 2023-07-21 | 美商特普醫葯公司 | 涉及二芳基巨環化合物之組合療法 |
| US20190134056A1 (en) * | 2017-03-10 | 2019-05-09 | The Trustees Of The Stevens Institute Of Technolog | K-ras mutations and antagonists |
| AU2018273356B2 (en) | 2017-05-22 | 2021-09-16 | Amgen Inc. | KRAS G12C inhibitors and methods of using the same |
| US10647715B2 (en) | 2017-11-15 | 2020-05-12 | Mirati Therapeutics, Inc. | KRas G12C inhibitors |
| LT3710439T (lt) | 2017-11-15 | 2023-05-10 | Mirati Therapeutics, Inc. | Kras g12c inhibitoriai |
| JP7060694B2 (ja) * | 2018-01-18 | 2022-04-26 | アレイ バイオファーマ インコーポレイテッド | Ｒｅｔキナーゼ阻害剤としての置換ピロロ［２，３－ｄ］ピリミジン化合物 |
| ES3017461T3 (en) | 2018-09-10 | 2025-05-13 | Mirati Therapeutics Inc | Combination of dasatinib and adagrasib for use in the treatment of non-small cell lung cancer |
| CN110256421A (zh) * | 2019-06-26 | 2019-09-20 | 微境生物医药科技(上海)有限公司 | Kras-g12c抑制剂 |
| MX2022006366A (es) * | 2019-11-27 | 2022-06-22 | Turning Point Therapeutics Inc | Terapia de combinacion que implica compuestos de diarilo macrociclico. |
| WO2021148581A1 (en) * | 2020-01-22 | 2021-07-29 | Onxeo | Novel dbait molecule and its use |
-
2020
- 2020-11-25 BR BR112022010278A patent/BR112022010278A2/pt unknown
- 2020-11-25 IL IL293206A patent/IL293206A/en unknown
- 2020-11-25 TW TW109141454A patent/TW202133855A/zh unknown
- 2020-11-25 EP EP20894516.2A patent/EP4065125A4/en active Pending
- 2020-11-25 KR KR1020227021852A patent/KR20220133866A/ko active Pending
- 2020-11-25 CN CN202080089330.6A patent/CN114901286B/zh active Active
- 2020-11-25 US US17/104,752 patent/US11654145B2/en active Active
- 2020-11-25 AU AU2020391222A patent/AU2020391222A1/en active Pending
- 2020-11-25 JP JP2022531006A patent/JP7670711B2/ja active Active
- 2020-11-25 WO PCT/US2020/062390 patent/WO2021108682A1/en not_active Ceased
- 2020-11-25 CA CA3162632A patent/CA3162632A1/en active Pending
- 2020-11-25 MX MX2022006500A patent/MX2022006500A/es unknown
-
2023
- 2023-04-24 US US18/138,644 patent/US20240033266A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| EP4065125A4 (en) | 2024-01-03 |
| JP2023505056A (ja) | 2023-02-08 |
| IL293206A (en) | 2022-07-01 |
| AU2020391222A1 (en) | 2022-06-30 |
| US11654145B2 (en) | 2023-05-23 |
| US20240033266A1 (en) | 2024-02-01 |
| CA3162632A1 (en) | 2021-06-03 |
| CN114901286B (zh) | 2024-05-10 |
| WO2021108682A1 (en) | 2021-06-03 |
| KR20220133866A (ko) | 2022-10-05 |
| MX2022006500A (es) | 2022-07-04 |
| CN114901286A (zh) | 2022-08-12 |
| EP4065125A1 (en) | 2022-10-05 |
| JP7670711B2 (ja) | 2025-04-30 |
| US20210220364A1 (en) | 2021-07-22 |
| TW202133855A (zh) | 2021-09-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112022010278A2 (pt) | Terapia combinada que envolve compostos macrocíclicos de diarila | |
| MX2019008701A (es) | Terapia de combinacion que involucra compuestos macrociclicos de diarilo. | |
| ZA201903125B (en) | 7-phenylethylamino-4h-pyrimido[4,5-d][1,3]oxazin-2-one compounds as mutant idh1 and idh2 inhibitors | |
| PH12020551244A1 (en) | Pd-1/pd-l1 inhibitors | |
| PH12021500004A1 (en) | Pd-1/pd-l1 inhibitors | |
| BR112021022812A2 (pt) | Dosagem de inibidor de kras para tratamento de cânceres | |
| BR112022022634A2 (pt) | Inibidores de atr para o tratamento de câncer | |
| BR112013000651A2 (pt) | combinações de inibidores de cinase para o tratamento de câncer. | |
| BR112022010277A2 (pt) | Terapia combinada que envolve compostos macrocíclicos de diarila | |
| BR112018004620A2 (pt) | moduladores da expressão de kras | |
| CR20240296A (es) | Inhibidores parp1 | |
| ECSP109918A (es) | Combinación de agente antimitótico e inhibidor de aurora quinasa como tratamiento anticancerígeno | |
| NI201000084A (es) | Tratamiento de cáncer de ovarios con un compuesto yodonitrobenzamida en combinación con agentes anti-tumorales | |
| NI201900096A (es) | Moduladores de la expresión de pcsk9 | |
| BR112022008295A2 (pt) | Inibição combinada de pd-1, tgfbeta e tigit para o tratamento de câncer | |
| ZA202004848B (en) | Modulators of irf4 expression | |
| MX2022001004A (es) | Inhibidores de enzimas. | |
| ZA202105742B (en) | Modulators of malat1 expression | |
| MX2022007626A (es) | Combinaciones. | |
| MX2020010721A (es) | Moduladores de la expresion de ezh2. | |
| MX2021002818A (es) | Métodos para tratar el cáncer mediante la inhibición de la enzima conjugadora de ubiquitina e2 k (ube2k). | |
| AR117094A1 (es) | Moduladores de expresión irf5 | |
| UY38472A (es) | Moduladores de la expresión de foxp3 | |
| MX2024012789A (es) | Inhibidores de fosfoinositida 3-cinasa alfa (pi3kalfa) | |
| AR117079A1 (es) | Moduladores de la expresión de foxp3 |